Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bramati

Showing results (181-190 of 193) with videos related to

Pageof 20
Sort By:
Tumori|October 10, 2014
Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysisElena Collovà, Antonella Ferzi, Giuseppa Scandurra, et al.
JAMA Oncology|July 31, 2025
Proportional Sedation for Persistent Agitated Delirium in Palliative Care: A Randomized Clinical TrialDavid Hui, Allison De La Rosa, Jaw-Shiun Tsai, et al.
Breast Cancer Research : BCR|October 29, 2022
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER studyNicla La Verde, Giovanna Damia, Ornella Garrone, et al.
Journal of Imaging Informatics in Medicine|December 16, 2025
Pixel Tampering: Does Face Redaction Harm Medical AI Performance?Eduardo M J M Farina, Felipe A Matsuoka, Gustavo Corradi, et al.
Scientific Reports|August 10, 2019
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant ChemotherapyAnnamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Scientific Reports|February 2, 2020
Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant ChemotherapyAnnamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Scientific Reports|November 6, 2014
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patientsAnnamaria Ruzzo, Francesco Graziano, Fabio Galli, et al.
British Journal of Cancer|October 25, 2017
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patientsA Ruzzo, F Graziano, Fabio Galli, et al.
Brain, Behavior, and Immunity|November 4, 2024
Cognitive, behavioral, neuroimaging and inflammatory biomarkers after hospitalization for covid-19 in BrazilFelipe Kenji Sudo, Talita P Pinto, Fernanda G Q Barros-Aragao, et al.
Antimicrobial Agents and Chemotherapy|October 17, 2018
Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in <i>Candida</i> and <i>Aspergillus</i> Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion MethodsA Espinel-Ingroff, J Turnidge, A Alastruey-Izquierdo, et al.
Pageof 20

Showing results (181-190 of 193) with videos related to

Sort By:
Pageof 20
Tumori|October 10, 2014
Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysisElena Collovà, Antonella Ferzi, Giuseppa Scandurra, et al.
JAMA Oncology|July 31, 2025
Proportional Sedation for Persistent Agitated Delirium in Palliative Care: A Randomized Clinical TrialDavid Hui, Allison De La Rosa, Jaw-Shiun Tsai, et al.
Breast Cancer Research : BCR|October 29, 2022
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER studyNicla La Verde, Giovanna Damia, Ornella Garrone, et al.
Journal of Imaging Informatics in Medicine|December 16, 2025
Pixel Tampering: Does Face Redaction Harm Medical AI Performance?Eduardo M J M Farina, Felipe A Matsuoka, Gustavo Corradi, et al.
Scientific Reports|August 10, 2019
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant ChemotherapyAnnamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Scientific Reports|February 2, 2020
Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant ChemotherapyAnnamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Scientific Reports|November 6, 2014
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patientsAnnamaria Ruzzo, Francesco Graziano, Fabio Galli, et al.
British Journal of Cancer|October 25, 2017
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patientsA Ruzzo, F Graziano, Fabio Galli, et al.
Brain, Behavior, and Immunity|November 4, 2024
Cognitive, behavioral, neuroimaging and inflammatory biomarkers after hospitalization for covid-19 in BrazilFelipe Kenji Sudo, Talita P Pinto, Fernanda G Q Barros-Aragao, et al.
Antimicrobial Agents and Chemotherapy|October 17, 2018
Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in <i>Candida</i> and <i>Aspergillus</i> Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion MethodsA Espinel-Ingroff, J Turnidge, A Alastruey-Izquierdo, et al.
Pageof 20